Gland Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on April 09, 2026.
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Gland Pharma's Board of Directors has approved the re-appointment of Ms. Naina Lal Kidwai as an Independent Director for a second term of five years, effective May 17, 2026 until May 16, 2031. Kidwai has been serving as an Independent Director since May 2021. She brings extensive experience including roles as Chairman of Rothschild & Co India, Senior Advisor at Advent Private Equity and TPG Rise Climate, and past positions at HSBC and Nestle. Her re-appointment requires shareholder approval through postal ballot and e-voting as per SEBI regulations. No disclosure of any relationships between the director and the company was flagged.
This is a routine governance matter confirming continuity of an experienced independent director on the board. The re-appointment is positive for corporate governance but is unlikely to have any material impact on the stock price in the short term.